Nov. 5, 2020—Hydroxychloroquine (HCQ) did not significantly reduce the incidence of COVID-19 among health care workers who participated in a national study that included Vanderbilt University Medical Center.
Nov. 5, 2020—How the National Institutes of Health (NIH) Rapid Acceleration of Diagnostics (RADx) initiative is accelerating development of COVID-19 testing will be the topic of this fall’s second web-based Discovery Lecture.
Nov. 2, 2020—Vanderbilt University Medical Center has begun recruiting up to 250 participants for a Phase 3 clinical trial testing an investigational COVID-19 vaccine candidate developed by the Janssen Pharmaceutical Companies of Johnson & Johnson.
Oct. 29, 2020—An innovative Vanderbilt program that brings together scientists and artists with the shared goal of scientific communication is set to expand with support from a three-year grant from the Burroughs Wellcome Fund.
Oct. 26, 2020—Researchers at Vanderbilt University Medical Center played a key role in the development of remdesivir, the first drug approved by the U.S. Food and Drug Administration for the treatment of COVID-19.
Oct. 22, 2020—Vanderbilt Genetics Institute investigators have added a new method to the computational genetics toolbox. Their approach, described in the journal Nature Genetics, integrates vast genomics datasets to predict gene expression and facilitate discovery of genetic mechanisms underlying human diseases.
Oct. 22, 2020—Craig Lindsley, PhD, the William K. Warren Jr. Chair in Medicine and University Professor of Pharmacology, Biochemistry and Chemistry, will become director of Vanderbilt University’s Warren Center for Neuroscience Drug Discovery (WCNDD), effective Dec. 1. Lindsley assumes the director position from Jeffrey Conn, PhD, Lee. E. Limbird Chair in Pharmacology and professor of Pharmacology.
Oct. 22, 2020—The Discovery Lecture Series launches this fall with a webinar format, the first featuring George Koob, PhD, director of the National Institute on Alcohol Abuse and Alcoholism (NIAAA), part of the National Institutes of Health.
Oct. 15, 2020—Researchers at Vanderbilt University Medical Center have identified a key factor that coordinates the body’s repair response to severe injury in the stomach caused, most commonly, by infection by the bacterium Helicobacter pylori.
COVID-19 long-acting antibodies discovered by Vanderbilt University Medical Center move to phase 3 clinical trials
Oct. 13, 2020—AstraZeneca is advancing into phase 3 clinical trials with an investigational COVID-19 therapy of two long-acting antibodies discovered by Vanderbilt University Medical Center and optimized by AstraZeneca.
Oct. 8, 2020—A computer-based method developed at Vanderbilt University Medical Center that scans electronic medical records (EMRs) for genetic contributors to disease has been used for the first time to reveal the impact of race on health.